These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23894728)

  • 1. Nanotechnology for CNS delivery of bio-therapeutic agents.
    Shah L; Yadav S; Amiji M
    Drug Deliv Transl Res; 2013 Aug; 3(4):336-51. PubMed ID: 23894728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery.
    Singh R; Brumlik C; Vaidya M; Choudhury A
    Recent Pat Nanotechnol; 2020; 14(3):174-192. PubMed ID: 32384043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
    Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
    Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: A review.
    Bellotti E; Schilling AL; Little SR; Decuzzi P
    J Control Release; 2021 Jan; 329():16-35. PubMed ID: 33259851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.
    Hanson LR; Frey WH
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):81-6. PubMed ID: 18040829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and physiological factors influencing CNS delivery upon intranasal administration.
    Vyas TK; Tiwari SB; Amiji MM
    Crit Rev Ther Drug Carrier Syst; 2006; 23(4):319-47. PubMed ID: 17341201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
    Dhuria SV; Hanson LR; Frey WH
    J Pharm Sci; 2010 Apr; 99(4):1654-73. PubMed ID: 19877171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson`s disease: Defining the Preclinical, Clinical and toxicity issues.
    Pathak K; Akhtar N
    Curr Drug Deliv; 2016 Jun; ():. PubMed ID: 27280392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
    Hanson LR; Frey WH
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.
    Wang GY; Rayner SL; Chung R; Shi BY; Liang XJ
    Mater Today Bio; 2020 Mar; 6():100055. PubMed ID: 32529183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
    Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
    Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.
    Dhuria SV; Hanson LR; Frey WH
    J Pharmacol Exp Ther; 2009 Jan; 328(1):312-20. PubMed ID: 18945930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobiotechnology-based drug delivery to the central nervous system.
    Jain KK
    Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.